All raw data is available through EMBL-EBI Array Express, accession number E-MTAB-3632.

Introduction {#sec001}
============

Amphibians are currently undergoing a mass extinction event \[[@pone.0130500.ref001]\]. Two key pathogens are known to be contributing to amphibian population declines and species extinctions: the fungus *Batrachochytrium dendrobatidis* (*Bd*) which causes chytridiomycosis, and the *Iridoviridae* genus *Ranavirus* \[[@pone.0130500.ref002]--[@pone.0130500.ref005]\]. *Bd* is a non-hyphal zoosporic fungus which causes mortalities on every continent except Antarctica (<http://www.bd-maps.net/>) and is thought to have caused multiple species extinctions \[[@pone.0130500.ref006]\]. *Ranaviruses* are large double-stranded DNA viruses, capable of crossing poikilothermic class boundaries, and implicated in mass die-off events and population declines \[[@pone.0130500.ref002],[@pone.0130500.ref005],[@pone.0130500.ref007]\]. *Ranavirus* and *Bd* are both noted for their virulence across a broad range of hosts but previous research on wild and captive animals points to contrasting levels of pathogenicity in European common frogs (*Rana temporaria*). Common frogs are highly susceptible to *Ranavirus* infection in the UK \[[@pone.0130500.ref005],[@pone.0130500.ref008]\] and Spain \[[@pone.0130500.ref007]\] but seem relatively resistant to *Bd* \[[@pone.0130500.ref009]\]. It is unknown whether this difference in susceptibility reflects differences in the host's immune response to each pathogen. *De novo* RNAseq offers an ideal opportunity to further our understanding of the host response to *Bd* and *Ranavirus*, allowing the identification of genes and pathways involved in the response to infection.

*Bd* is thought to kill its host by disrupting the cutaneous integrity and function of amphibian skin \[[@pone.0130500.ref010]\]. Transcriptome sequencing has suggested that more resistant hosts may increase expression of genes involved in skin structure \[[@pone.0130500.ref011]\] and dramatic up and down-regulation of pathways relating to collagen, fibrinogen, elastin and keratin have been reported in the skin of adult amphibians experimentally infected with *Bd* \[[@pone.0130500.ref012]\]. Enrichment of inflammatory responses when challenged with *Bd* may be a general response regardless of susceptibility \[[@pone.0130500.ref011],[@pone.0130500.ref013]\]. Increased expression of microbial peptides in response to *Bd* infection has also been identified in several species (*Rana sierrae*, *Rana muscosa* adults \[[@pone.0130500.ref012]\]; *Xenopus tropicalis* adults \[[@pone.0130500.ref014]\]), indicating that innate immunity is a component of host defence. Robust adaptive immunogenetic responses to *Bd* infection have in general not been observed, but components of innate and adaptive immunity have been shown to operate even in species that are highly susceptible \[[@pone.0130500.ref013]\]. In addition significant up and down regulation of adaptive immune genes (including the Major Histocompatibility Complex (MHC) class I and II in particular) have been shown in experimentally infected adult ranids \[[@pone.0130500.ref012],[@pone.0130500.ref014]\] and a comparison of responses to *Bd* in hosts of varying susceptibility suggested that the ability to escape immunosuppression by mounting T-cell mediated responses may determine resistance \[[@pone.0130500.ref011]\]. Our understanding of the response of juveniles to *Bd* remains limited.

To date, there has been one study of the transcriptional response of amphibians to *Ranavirus*. *Ambystoma mexicanum* (axolotl) showed a significant immunological response when experimentally challenged with the *Ranavirus Ambystoma tigrinum virus* (ATV) \[[@pone.0130500.ref015]\]. Wild ambystomatid salamanders are highly susceptible to ATV, however experimental animals appeared to mount an immune response to infection within 24 hours of exposure. Using spleen tissues processed through microarrays, the authors demonstrated changes in the expression of innate immunity genes and the transcriptional response increased through time \[[@pone.0130500.ref015]\]. Experimental infection of adult *Xenopus laevis* with a strain of *Ranavirus* (FV3) has demonstrated increased expression of pro-inflammatory cytokines e.g. tumour necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β), indicating that (like for *Bd*) the innate immune response is activated following infection \[[@pone.0130500.ref016]\]. Tadpoles show weaker and more delayed up-regulation of these genes \[[@pone.0130500.ref017]\]. Specific MHC class Ia gene supertypes have been found to be associated with infection status of adult wild common frog (*R*. *temporaria*) populations, and diseased populations are characterized by more similar supertype frequencies (lower *F* ~ST~) than infected populations, indicating pathogen-driven selection on the MHC \[[@pone.0130500.ref018]\]. This implies that an adaptive immune response to *Ranavirus* occurs in *R*. *temporaria*, and may be important for survival after infection. While adult *Xenopus laevis* are able to clear FV3 infections, tadpoles do not appear to mount an adaptive immune response to FV3, and succumb to infection within a month of inoculation \[[@pone.0130500.ref017]\]. Again, little is known about the immune response of juveniles. In general, metamorphosis is a critical point in amphibian immunity--the adaptive immune response appears to be limited pre-metamorphosis, the innate immune response is transformed at metamorphosis, and during metamorphosis individuals are thought to experience temporary immunosuppression \[[@pone.0130500.ref019]\].

In order to better understand the host response to *Bd* and *Ranavirus*, in this study we (i) used RNAseq to generate an annotated de-novo transcriptome for the common frog (*R*. *temporaria*) (ii) conducted comparative expression profiling of the early responses of metamorphic frogs exposed to *Bd* or *Ranavirus* relative to control animals, and (iii) identified candidate genes for future studies on the population-level impacts of these pathogens.

Methods {#sec002}
=======

Experimental treatments {#sec003}
-----------------------

*Ranavirus* (RUK13 isolate; \[[@pone.0130500.ref020]\]) was cultured at 24ºC in Fathead Minnow cells (FHM, Epithelial-like cells from the posterior anal tissue, obtained from the European Collection of Cell Cultures catalogue number 88102401) in maintenance media (EMEM + 10% FBS + 1% L-Glutamine) and quantified on 96 well flat-bottomed cell culture plates using the TCID~50~ method \[[@pone.0130500.ref021]\]. *Bd* inoculum (Isolate IA 042, *Bd*GPL; \[[@pone.0130500.ref022]\]) was prepared by culture in mTGhL medium at 18ºC for four days before counting zoospores using a haemocytometer.

*R*. *temporaria* eggs were obtained from a private garden pond in Chessington in the UK with the permission of the landowner \[[@pone.0130500.ref005]\]. This site has a known history of *Ranavirus* infection, but an unknown history of *Bd* infection. The eggs were hatched and reared through metamorphosis under controlled conditions, showing good survival and no signs of infection. Metamorphs (*n* = 45) were moved into an experimental room (18-21ºC, 33--46% humidity, full spectrum UV light) for acclimatisation one week prior to exposure, and were placed in individual boxes and fed on crickets ad libitum.

This work was carried out under Home Office license (Project Licence numbers PPL 80/2214 and PPL 80/2466) and was approved by the Institute of Zoology Ethics Committee and the University of Exeter Ethical Review Board. In total 45 frogs were used---15 animals for each of three exposure treatments (*Ranavirus*, *Bd*, Control). Animals were checked, cleaned and given fresh water frequently whilst being mindful of causing them distress through unnecessary handling. Exposure was performed in individual tubes with 29ml aged tap water with 1ml of inoculum (*Ranavirus* at 1k TCID~50~/ml or *Bd* at 100k active zoospores/ml), or 30ml tap water for the control treatment, for four hours. Following exposure, the frogs were returned to their individual boxes and examined daily for signs of *Ranavirus* infection (oedema of the eye, skin ulceration, bleeding), which would have served as an endpoint for the experiment but none were observed. Frogs were euthanized according to Schedule 1 to the Animals (Scientific Procedures) Act 1986 four days post-exposure by immersion in fresh 5g/L Tricaine methane sulphonate (MS222, Pharmaq Ltd.) solution neutralized with sodium bicarbonate in accordance with Universities Federation for Animal Welfare guidance to ameliorate suffering. We sampled livers because they are large, easily targeted organs which are important for immunity and are a target organ in ranavirus disease \[[@pone.0130500.ref023]\]. Livers were immediately dissected, preserved individually in RNAlater solution (Sigma Aldrich), and stored at -80ºC.

Sequencing, de novo assembly and abundance estimation {#sec004}
-----------------------------------------------------

Total RNA was extracted from 5--20μg of liver tissue using the Qiagen RNeasy Mini Kit (Qiagen, Valencia USA) using the standard protocol. Each treatment consisted of 15 frogs; three pools were sequenced per treatment, with five individuals per pool. We therefore prepared nine samples for sequencing; 3 replicates per treatment, each consisting of pooled RNA extracted from the livers of 5 individuals. RNA concentration was estimated using a NanoDrop (NanoDrop, Wilmington USA), and concentrations of individual sample extractions were equalized within pools, resulting in a total pool volume of 80μl (concentrations varied between pools, Supporting Information [S1 table](#pone.0130500.s002){ref-type="supplementary-material"}). The sample concentrations were not normalized. DNase treatment, library preparation and 100 base pair paired-end sequencing were performed at the Wellcome Trust Biomedical Informatics Hub using an Illumina HiSeq 2500 with two samples per lane.

Raw reads were processed with the fastq-mcf package (ea-utils; <https://code.google.com/p/ea-utils/wiki/FastqMcf>; \[[@pone.0130500.ref024]\]) to trim low quality bases and adaptor sequences from the ends of reads and remove short reads as well as those containing non-assigned bases (Ns). The following settings were used: quality threshold of 20, minimum remaining sequence length of 35, minimum identity between adapter sequence and clipped sequence of 85%, no Ns permitted, and a minimum clip length of 3. The results were then evaluated using FastQC \[[@pone.0130500.ref025]\]. Reads from all samples were combined and processed through the standard Trinity pipeline (r2013-02-25 release) for *de novo* RNAseq assembly \[[@pone.0130500.ref026]\]. Assembly computation requirements were reduced by performing *in silico* normalization on the reads to reduce the total number of reads and remove errors whilst maintaining transcriptome complexity (maximum coverage for reads = 30; minimum kmer coverage for catalogue construction = 2). Isotigs were assembled along Trinity's three-stage protocol (Inchworm, Chrysalis, Butterfly) with default settings including a minimum isotig length of 200bp. Transcript abundance estimates for each sample were obtained using RSEM (packaged with Trinity) \[[@pone.0130500.ref027]\].

Functional annotation and comparative transcription rates {#sec005}
---------------------------------------------------------

The assembled transcriptome was annotated using Trinotate, a suite of programs for functional annotation of transcriptomes that is suitable for use with non-model organisms. Sequences were processed through a pipeline consisting of a homology search (NCBI-BLAST), protein domain identification (HMMER/PFAM), protein signal prediction (singalP/tmHMM), and comparison to EMBL Uniprot eggNOG and the GO Pathways annotation databases \[[@pone.0130500.ref028]--[@pone.0130500.ref037]\].

The reference assembly was filtered prior to differential expression analysis so that the assembly used for downstream analyses might better reflect transcribed genes and to reduce the number of comparisons undertaken. Filtering was based on the number of mapped reads. Assembled isotigs were retained only if the FPKM (expected fragments per kilobase of transcript per million fragments sequenced \[[@pone.0130500.ref038]\]) was greater than or equal to one for all three replicates within one or more treatments (FPKM ≥ 1).

We used the CEGMA pipeline to accurately annotate Core Eukaryotic Genes (CEGs; \[[@pone.0130500.ref039]\]). CEGMA can be used to assess assembly completeness and the impact of downstream filtering steps via the proportion of core genes present. This proportion is calculated relative to a reference set containing 248 of the most highly conserved CEGs and analysis suggests it is a good metric to assess completeness of draft assemblies \[[@pone.0130500.ref040]\]. We ran CEGMA with default settings on our reference (unfiltered) and FPKM ≥ 1 filtered assemblies to obtain the number of complete \[more than 70% of the protein length aligned to isotig(s)\] and partial \[alignment length is less than 70% but remains higher than a minimum alignment threshold\] core genes that these assemblies contained.

Differential expression analysis was performed with edgeR using a Trinity packaged Perl script. Subsets of differentially expressed transcripts were compiled based on log-fold change of one and Benjamini--Hochberg adjusted p-values \[[@pone.0130500.ref041]\] to control for false discovery rate \[FDR\<0.05 to obtain the transcript list and FDR\<0.10 for downstream Gene Ontology (GO) term enrichment analysis\]. All pairwise comparisons were considered; *Bd* vs. control, *Ranavirus* vs. control, and *Bd* vs. *Ranavirus*. Differentially expressed transcripts in the *Bd* vs. *Ranavirus* comparison were allocated to either *Bd* or *Ranavirus* ([S1 Text](#pone.0130500.s001){ref-type="supplementary-material"}).

Analysis of Gene Ontology term enrichment {#sec006}
-----------------------------------------

Bingo (a Cytoscape plugin; \[[@pone.0130500.ref042]\]) was used to search for GO term enrichment (identifying which GO terms are over or under-represented). Bingo compares the list of differentially expressed products to a user generated list of all genes/transcripts and is therefore of particular use for research on non-model organisms. EdgeR subsets of differentially expressed transcripts at FDR = 0.05 and FDR = 0.10 were analyzed.

Results {#sec007}
=======

Sequencing, Assembly and annotation {#sec008}
-----------------------------------

A total of 1.29 x 10^9^ reads were generated across all nine samples with a mean quality score of 35.2. All raw data is available through EMBL-EBI Array Express, accession number E-MTAB-3632. In total, 199,602 isotigs were generated with an N50 isotig length of 1,086 base pairs and 30,931 isotigs longer than 1,000bp. There were 134,080,068 bases contained in all isotigs with a GC content of 44%. Assembly summary statistics are shown in [Table 1](#pone.0130500.t001){ref-type="table"}. Trinotate generated a list of 48,263 annotated isotigs from 32,486 disconnected subgraphs. These isotigs hit 17,631 genes when orthologs were included and 11,851 genes when excluding orthologs. The species with the highest number of hits were humans (5,605 genes), mouse (3,800), *Xenopus laevis* (1,720), rat (1,382), cow (1,154) and *Xenopus tropicalis* (1,035). In total, 71--76% of reads mapped back to the reference assembly from each set of sample reads (i.e. as part of RSEM analysis); control 73--76%, *Ranavirus 7*1--74%, *Bd* 72--74%.

10.1371/journal.pone.0130500.t001

###### Trinity assembly summary statistics.

![](pone.0130500.t001){#pone.0130500.t001g}

  -------------------------------------------------- -------------
  [**Isotig lengths:**]{.ul}                         
  Minimum isotig length:                             201
  Maximum isotig length:                             18,036
  Mean isotig length:                                672
  Standard deviation of isotig length:               944
  Median isotig length:                              352
  N50 isotig length:                                 1,086
  [**Numbers of isotigs:**]{.ul}                     
  Number of isotigs:                                 199,602
  Number of isotigs more than 1kb in length:         30,931
  Number of isotigs in N50:                          28,238
  [**Number of bases in assembled isotigs:**]{.ul}   
  Number of bases in all isotigs:                    134,080,068
  Number of bases in isotigs \> = 1kb in length:     69,845,219
  GC Content of isotigs:                             43.95%
  -------------------------------------------------- -------------

The reference assembly was almost complete when compared to CEGMA's 248 CEG set, giving us confidence that our methods have yielded an assembly that is a good approximation to the actual transcriptome. In total, 240 (of 248; 97%) complete CEGs and an additional six partial CEGs (total = 246 of 248; 99%) were found in our reference assembly. Summary statistics measuring the completeness of the assembly (broken down by KOG group) are included in [S2 Table](#pone.0130500.s003){ref-type="supplementary-material"}.

Some genes were lost through our filtering operation but a large majority of CEGs remained. The FPKM ≥ 1 filtered assembly contained 215 (87%) complete genes out of the 248 most highly conserved CEGs. A further five partial genes were present giving a total of 220 CEGs (89%; [S2 Table](#pone.0130500.s003){ref-type="supplementary-material"}).

Differential expression {#sec009}
-----------------------

Transcriptional profiles of replicates were consistent within treatments, clustering together within treatments when expression values were compared for each pair of samples ([Fig 1](#pone.0130500.g001){ref-type="fig"}). Expression values were more similar within the *Ranavirus* and control treatments than in the more divergent *Bd* treatment. The total number of differentially expressed transcripts that we report was affected by the False Discovery Rate (FDR), as well as our procedure for re-allocating some differentially expressed transcripts from the *Bd* vs. *Ranavirus* comparisons to the other comparisons ([Table 2](#pone.0130500.t002){ref-type="table"}; [Fig 2](#pone.0130500.g002){ref-type="fig"}). Increasing the FDR increased the number of differentially expressed transcripts in our output. Classifying some of the *Bd* vs. *Ranavirus* transcripts to *Bd* or *Ranavirus* vs. control ([S1 Text](#pone.0130500.s001){ref-type="supplementary-material"}) also increased the number of transcripts for each pathogen vs. control comparison but reduced the total number of unique differentially expressed transcripts because, for example, some of these transcripts were due to small but opposite effects of the two pathogens compared to controls.

![Comparison of transcriptional profiles across all samples.\
Heatmap visualizing the hierarchically clustered Spearman correlation matrix resulting from a comparison of the transcript expression values (TMM-normalized FPKM) for each pair of samples; Bd = *Batrachochytrium dendrobatidis*, Con = control, Rv = *Ranavirus*.](pone.0130500.g001){#pone.0130500.g001}

![Venn diagrams showing distribution of differentially expressed transcripts across comparisons of treatments.\
*Bd* vs. control, *Ranavirus* vs. control, and *Bd* vs. *Ranavirus* at a) FDR \< 0.05 & b) FDR \< 0.10.](pone.0130500.g002){#pone.0130500.g002}

10.1371/journal.pone.0130500.t002

###### Summary of the total number of differentially expressed transcripts under alternate FDR regimes: FDR \<0.05, FDR\<0.10, and differentially expressed transcripts from the *Bd*-*Ranavirus* comparison at FDR\<0.10 allocated to one of the other comparisons ([S1 Text](#pone.0130500.s001){ref-type="supplementary-material"}).

![](pone.0130500.t002){#pone.0130500.t002g}

                                                                   FDR         
  ---------------------------------------------------------------- ----- ----- -----
  *Bd* vs. control                                                 120   315   360
  *Ranavirus* vs. control                                          23    34    65
  *Bd* vs. *Ranavirus*                                             58    136   n/a
  Both pathogens vs. control                                       5     10    18
  Total unique[^†^](#t002fn001){ref-type="table-fn"} transcripts   174   419   407

† some transcripts are differentially expressed in more than one pairwise comparison. This total accounts for this repetition by counting each differentially expressed transcript once only.

Exposure to *Bd* elicited far greater transcriptional divergence from controls than did exposure to *Ranavirus* ([Table 2](#pone.0130500.t002){ref-type="table"}, [Fig 3](#pone.0130500.g003){ref-type="fig"}; 120 differentially expressed transcripts for *Bd* compared to 23 for *Ranavirus* at FDR\<0.05). After allocation of the *Bd* vs. *Ranavirus* transcripts to one of the pathogen treatments, there were a total of 360 transcripts (294 up-regulated, 66 down-regulated, 122 annotated) for *Bd* and 65 (35 up-regulated, 30 down-regulated, 16 annotated) for *Ranavirus* ([Fig 4](#pone.0130500.g004){ref-type="fig"}). The overall tendency for up-regulated expression in *Bd*-exposed animals was not seen in *Ranavirus*-exposed animals ([Fig 4](#pone.0130500.g004){ref-type="fig"}). Amongst annotated transcripts that were differentially expressed after *Bd* challenge, interferon-induced proteins figure prominently through Interferon-stimulated 20kDa exonuclease-like 2 and multiple versions of Interferon-induced very large GTPase 1 proteins ([Table 3](#pone.0130500.t003){ref-type="table"}).

![Relative expression of differentially expressed (FDR \< 0.05) transcripts (rows) across all samples (columns).\
Dendrograms show relationships between samples based on expression values (top) and between transcripts based on comparative expression across samples (left). Bd = *Batrachochytrium dendrobatidis*, Con = control, Rv = *Ranavirus*.](pone.0130500.g003){#pone.0130500.g003}

![Counts of up- and down-regulated transcripts in response to *Bd* and *Ranavirus*.\
Data are summarized at alternate false-discovery rate levels (FDR \< 0.05 & FDR \< 0.10) and following re-allocation of transcripts in the *Bd* vs. *Ranavirus* comparison.](pone.0130500.g004){#pone.0130500.g004}

10.1371/journal.pone.0130500.t003

###### Differentially expressed transcripts (all comparisons, FDR = 0.05, log-fold-change = 1) that were successfully annotated.

![](pone.0130500.t003){#pone.0130500.t003g}

  Transcript ID         Comparison   logFC   logCPM   PValue     FDR        Bd1     Bd2      Bd3     Con1    Con2     Con3    Rv1     Rv2     Rv3     Name          Accession   Protein name                                                        Expect Value   Associated with enriched GO term?
  --------------------- ------------ ------- -------- ---------- ---------- ------- -------- ------- ------- -------- ------- ------- ------- ------- ------------- ----------- ------------------------------------------------------------------- -------------- -----------------------------------
  comp239933_c4_seq3    bd           10.91   1.33     5.03E-26   9.86E-22   4.41    2.28     2.54    0       0        0       0.4     3.79    0.9     AP4S1_BOVIN   Q3ZBB6      AP-4 complex subunit sigma-1                                        E:5e-86        
  comp229785_c0_seq2    bd           6.08    5.80     3.42E-06   3.20E-03   1.25    112.48   1.45    0.35    0.63     0.76    2.42    1.03    0.5     PRVB_RANES    P02617      Parvalbumin beta                                                    E:2e-55        yes
  comp181434_c0_seq2    bd           4.41    2.49     2.27E-06   2.34E-03   1.88    29.12    1.47    0.6     0.5      0.44    0.68    0.51    0.65    ACT3_XENLA    P04752      Actin, alpha skeletal muscle 3                                      E:0            
  comp103973_c0_seq2    bd           4.29    1.64     4.07E-07   6.34E-04   7.53    2.71     14.08   0.43    0.92     0.04    0.37    0.85    0       GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:2e-61        
  comp242668_c0_seq7    bd           3.08    1.02     6.67E-05   2.40E-02   1.98    1.53     1.81    0.35    0        0.34    0.92    0.45    0.21    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:6e-88        
  comp242668_c0_seq10   bd           2.98    0.30     3.75E-05   1.84E-02   2.72    2.1      2.45    0.1     0.83     0.05    0.41    0.86    0       GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:3e-117       
  comp239447_c0_seq9    bd           2.97    0.98     2.19E-04   3.94E-02   1.8     3.46     1.04    0       0.57     0.29    0.24    1.32    0       ATF4_RAT      Q9ES19      Cyclic AMP-dependent transcription factor ATF-4                     E:9e-103       
  comp242668_c0_seq9    bd           2.67    0.53     6.01E-06   5.12E-03   3.53    2.87     5.16    0.29    0.46     1.31    2.5     1.01    1.49    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:5e-85        
  comp91414_c0_seq1     bd           2.56    2.89     8.10E-06   6.62E-03   3.8     24.69    7.71    2.15    2.31     1.96    2.78    1.57    2.08    ALDOA_HUMAN   P04075      Fructose-bisphosphate aldolase A                                    E:1e-136       
  comp224799_c0_seq2    bd           2.56    0.11     1.02E-04   2.90E-02   6.6     2.21     6.65    1.08    1.5      0.3     0.38    1.97    0.41    GVIN1_MOUSE   Q80SU7      Interferon-induced very large GTPase 1                              E:7e-06        
  comp242668_c0_seq13   bd           2.45    4.11     9.82E-09   2.41E-05   9.74    6.38     10.96   1.29    1.64     2.63    6.22    2.19    3.1     GVIN1_MOUSE   Q80SU7      Interferon-induced very large GTPase 1                              E:1e-157       
  comp242668_c0_seq6    bd           2.43    2.88     8.95E-08   1.60E-04   5.27    2.75     5.09    0.79    1.23     0.67    1.57    1.49    0.39    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:0            
  comp242668_c0_seq1    bd           2.42    4.39     4.85E-07   6.34E-04   12.38   7.36     16.85   1.4     3.81     2.5     5.6     4.53    1.79    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:3e-68        
  comp511272_c0_seq1    bd           2.42    -0.05    1.61E-04   3.29E-02   2.32    2.68     8.25    0.95    1.11     0.71    0.48    1.96    2.44    ANGT_RAT      P01015      Angiotensinogen                                                     E:2e-06        yes
  comp242668_c0_seq3    bd           2.37    3.42     4.52E-07   6.34E-04   7.75    4.4      11.14   1.03    1.79     2.3     4.32    2.38    2.82    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:0            
  comp242026_c1_seq5    bd           2.32    2.31     4.84E-06   4.32E-03   2.18    3.4      3.65    0.98    0.7      0.32    2.49    2.64    1.43    LIAS_XENLA    Q6GQ48      Lipoyl synthase, mitochondrial                                      E:0            
  comp283381_c0_seq1    bd           2.14    1.99     1.33E-04   3.13E-02   9.61    3.37     12.88   2.61    1.42     2.53    4.93    1.48    5.41    AGLUS_METJA   Q58746      Archaeal glutamate synthase \[NADPH\]                               E:6e-154       
  comp351995_c0_seq1    bd           2.06    0.65     1.77E-04   3.47E-02   2.61    1.68     4.52    0.91    0.64     0.81    1.4     1.04    1.4     TCPZ_CHICK    Q5ZJ54      T-complex protein 1 subunit zeta                                    E:7e-112       
  comp349197_c0_seq1    bd           2.05    -1.04    2.73E-04   4.58E-02   1.53    1.23     2.2     0.42    0.42     0.46    0.88    0.45    0.7     GCP4_MOUSE    Q9D4F8      Gamma-tubulin complex component 4                                   E:5e-58        
  comp90672_c0_seq1     bd           2.02    -0.55    1.37E-04   3.13E-02   2.37    1.33     2.17    0.53    0.53     0.53    1.02    0.85    1.07    PTN1_CHICK    O13016      Tyrosine-protein phosphatase non-receptor type 1                    E:2e-89        
  comp225219_c0_seq1    bd           2.01    1.84     1.10E-04   3.05E-02   10.54   6.86     11.4    1.85    4.49     1.52    2.8     3.22    0.24    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:1e-36        
  comp241555_c2_seq2    bd           1.99    1.50     4.19E-05   1.96E-02   2.79    2.14     1.82    0.36    0.49     1.01    1.93    1.3     0.3     MESH1_XENTR   Q28C98      Guanosine-3\',5\'-bis(diphosphate) 3\'-pyrophosphohydrolase MESH1   E:3e-97        
  comp229974_c0_seq1    bd           1.96    2.16     2.46E-06   2.41E-03   4.02    4.63     5.61    1.15    1.37     1.51    1.6     5.18    5.9     UCP2_CYPCA    Q9W725      Mitochondrial uncoupling protein 2                                  E:1e-171       
  comp94070_c0_seq1     bd           1.92    1.66     1.57E-04   3.29E-02   9.58    4.32     11.86   1.91    2.74     2.97    3.68    2.42    4.34    CCNI_HUMAN    Q14094      Cyclin-I                                                            E:1e-73        
  comp222706_c0_seq1    bd           1.83    2.97     1.33E-04   3.13E-02   10.14   7.78     22.32   4.03    4.51     4.21    6.39    6.42    7.46    I20L2_BOVIN   Q2YDK1      Interferon-stimulated 20 kDa exonuclease-like 2                     E:2e-82        
  comp229273_c0_seq1    bd           1.79    1.21     1.36E-04   3.13E-02   1.31    1.18     1.97    0.49    0.49     0.45    0.36    0.46    0.5     RN145_MOUSE   Q5SWK7      RING finger protein 145                                             E:0            
  comp212366_c0_seq1    bd           1.78    3.49     1.39E-04   3.13E-02   20.21   14.26    43.21   7.65    8.68     9.17    11.28   10.4    17.08   SF3A1_BOVIN   A2VDN6      Splicing factor 3A subunit 1                                        E:5e-51        
  comp197838_c0_seq1    bd           1.71    3.96     1.52E-04   3.29E-02   11.96   7.56     22.38   4.25    4.74     5.45    4.97    3.87    9.34    AGFG1_HUMAN   P52594      Arf-GAP domain and FG repeat-containing protein 1                   E:3e-174       
  comp225693_c0_seq1    bd           1.61    3.51     2.06E-04   3.82E-02   19.41   13.65    33.7    7.4     8.68     8.52    13.25   9.22    9.2     TDX_CYNPY     Q90384      Peroxiredoxin                                                       E:9e-123       
  comp241884_c0_seq6    bd           -1.66   2.25     4.48E-05   1.98E-02   0.58    0.6      0.77    2.19    2.2      2.37    1.52    2.12    0.42    METK1_HUMAN   Q00266      S-adenosylmethionine synthase isoform type-1                        E:0            
  comp242157_c2_seq1    bd           -1.66   2.77     1.60E-04   3.29E-02   0.59    0.68     1.09    2.49    2.03     3.78    1.24    3.31    1.96    DNJB9_MOUSE   Q9QYI6      DnaJ homolog subfamily B member 9                                   E:3e-115       
  comp230044_c0_seq1    bd           -1.78   1.57     2.16E-04   3.92E-02   0.8     1.27     1.39    5.75    3.07     4.02    3.56    2.46    0.94    LDLR1_XENLA   Q99087      Low-density lipoprotein receptor 1                                  E:2e-149       yes
  comp234135_c0_seq1    bd           -1.82   1.79     8.43E-05   2.58E-02   0.89    1.05     1.25    5.47    2.99     3.76    2.91    2.37    1.08    LDLR2_XENLA   Q99088      Low-density lipoprotein receptor 2                                  E:0            yes
  comp234135_c0_seq2    bd           -1.90   1.21     8.52E-05   2.58E-02   1.93    1.43     1.41    8.4     4        6.96    4.33    3.49    1.56    LDLR1_XENLA   Q99087      Low-density lipoprotein receptor 1                                  E:1e-41        yes
  comp225798_c0_seq3    bd           -1.93   3.57     1.12E-05   8.45E-03   6.06    3.65     4.11    26.68   11.04    19.18   15.04   25.74   4.57    GRP78_XENLA   Q91883      78 kDa glucose-regulated protein                                    E:7e-120       
  comp225798_c0_seq1    bd           -2.07   6.00     2.81E-05   1.60E-02   7.83    5.24     12.8    28.98   26.02    68.9    21.59   44.4    21.21   GRP78_XENLA   Q91883      78 kDa glucose-regulated protein                                    E:0            
  comp235980_c0_seq10   bd           -2.34   0.51     1.87E-04   3.60E-02   0.22    0.06     0.33    1.47    0.7      1.31    1.87    1.73    1.16    GPBP1_MOUSE   Q6NXH3      Vasculin                                                            E:8e-146       
  comp233358_c0_seq1    bd           -2.71   1.47     8.65E-09   2.41E-05   0.39    0.3      0.29    2.67    2.54     1.83    0.53    0.32    0       ACSM3_MOUSE   Q3UNX5      Acyl-coenzyme A synthetase ACSM3, mitochondrial                     E:0            
  comp236082_c0_seq2    bd           -2.95   2.10     9.57E-12   3.76E-08   0.33    0.42     0.28    2.7     3.32     2.55    5.57    1.28    1.75    FMO5_RABIT    Q04799      Dimethylaniline monooxygenase \[N-oxide-forming\] 5                 E:0            
  comp238162_c2_seq1    bd           -3.34   -0.48    7.85E-08   1.54E-04   0.11    0.02     0.18    1.24    1.05     1.13    0.4     0.5     0.27    OVCA2_XENTR   A4II73      Ovarian cancer-associated gene 2 protein homolog                    E:2e-110       
  comp239921_c0_seq17   bd           -4.27   2.03     1.46E-05   1.06E-02   0.04    0        0.37    2.45    2.02     4.76    3.95    0.11    1.81    ECH1_RAT      Q62651      Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial          E:6e-150       
  comp242544_c0_seq7    bd           -6.32   1.26     4.00E-21   3.92E-17   0       0.07     0.04    2.48    3.86     2.68    0.34    4.06    1.03    CK054_XENLA   Q6GME2      Ester hydrolase C11orf54 homolog                                    E:0            
  comp234419_c0_seq2    bd           -7.46   0.76     4.32E-07   6.34E-04   0.01    0        0       0       1.75     1.95    1.16    1.45    2.04    FA73B_XENLA   Q6GR21      Protein FAM73B                                                      E:0            
  comp229785_c0_seq2    bd_rv        4.90    5.89     1.42E-04   4.89E-02   1.25    112.48   1.45    0.35    0.63     0.76    2.42    1.03    0.5     PRVB_RANES    P02617      Parvalbumin beta                                                    E:2e-55        yes
  comp103973_c0_seq2    bd_rv        4.55    1.67     3.77E-07   5.28E-04   7.53    2.71     14.08   0.43    0.92     0.04    0.37    0.85    0       GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:2e-61        
  comp181434_c0_seq2    bd_rv        4.16    2.56     7.23E-06   5.46E-03   1.88    29.12    1.47    0.6     0.5      0.44    0.68    0.51    0.65    ACT3_XENLA    P04752      Actin, alpha skeletal muscle 3                                      E:0            
  comp224799_c0_seq2    bd_rv        2.67    0.13     1.46E-04   4.94E-02   6.6     2.21     6.65    1.08    1.5      0.3     0.38    1.97    0.41    GVIN1_MOUSE   Q80SU7      Interferon-induced very large GTPase 1                              E:7e-06        
  comp214878_c0_seq1    bd_rv        2.65    3.17     1.25E-04   4.64E-02   16.34   12.63    9.1     10.8    0.63     0       0.39    1.37    4.6     MFAP4_BOVIN   P55918      Microfibril-associated glycoprotein 4                               E:7e-74        
  comp91414_c0_seq1     bd_rv        2.56    2.94     2.16E-05   1.32E-02   3.8     24.69    7.71    2.15    2.31     1.96    2.78    1.57    2.08    ALDOA_HUMAN   P04075      Fructose-bisphosphate aldolase A                                    E:1e-136       
  comp229401_c0_seq1    bd_rv        2.14    1.63     2.95E-05   1.70E-02   3.67    2.54     4.79    0.75    0.63     3.05    1.23    0.61    0.92    NB5R3_BOVIN   P07514      NADH-cytochrome b5 reductase 3                                      E:4e-155       
  comp242668_c0_seq6    bd_rv        2.10    2.98     9.08E-05   3.71E-02   5.27    2.75     5.09    0.79    1.23     0.67    1.57    1.49    0.39    GVIN1_HUMAN   Q7Z2Y8      Interferon-induced very large GTPase 1                              E:0            
  comp215007_c0_seq2    bd_rv        2.09    -0.04    8.85E-05   3.69E-02   2.06    1.91     0.9     1.06    1.57     1.96    0.34    0.59    0.31    ABCA8_HUMAN   O94911      ATP-binding cassette sub-family A member 8                          E:1e-87        
  comp229273_c0_seq1    bd_rv        1.90    1.23     1.10E-04   4.31E-02   1.31    1.18     1.97    0.49    0.49     0.45    0.36    0.46    0.5     RN145_MOUSE   Q5SWK7      RING finger protein 145                                             E:0            
  comp237274_c0_seq1    bd_rv        1.57    3.80     7.01E-05   3.12E-02   12.22   8.48     9.59    5.89    6.67     5.81    3.96    4.64    2.63    GLCTK_RAT     Q0VGK3      Glycerate kinase                                                    E:5e-166       
  comp234903_c0_seq1    bd_rv        -2.16   1.76     1.43E-05   1.00E-02   0.36    0.25     0.54    0.59    3.55     0.95    1.53    2.32    1.89    RBM5_XENTR    A4IGK4      RNA-binding protein 5                                               E:0            
  comp203468_c0_seq1    bd_rv        -2.49   1.52     6.96E-07   8.03E-04   1.47    1.27     0.69    9.75    0        6.96    4.56    8.09    8.14    IGJ_MOUSE     P01592      Immunoglobulin J chain                                              E:2e-44        yes
  comp235980_c0_seq10   bd_rv        -2.78   0.95     5.85E-06   4.59E-03   0.22    0.06     0.33    1.47    0.7      1.31    1.87    1.73    1.16    GPBP1_MOUSE   Q6NXH3      Vasculin                                                            E:8e-146       
  comp236082_c0_seq2    bd_rv        -2.95   2.16     6.42E-07   7.87E-04   0.33    0.42     0.28    2.7     3.32     2.55    5.57    1.28    1.75    FMO5_RABIT    Q04799      Dimethylaniline monooxygenase \[N-oxide-forming\] 5                 E:0            
  comp239921_c0_seq2    bd_rv        -3.87   2.53     6.42E-05   3.00E-02   0.04    0.95     0.05    1.76    0.98     12.33   9.38    4.76    1.84    ECH1_RAT      Q62651      Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial          E:6e-150       
  comp242544_c0_seq7    bd_rv        -5.50   0.57     1.97E-08   4.84E-05   0       0.07     0.04    2.48    3.86     2.68    0.34    4.06    1.03    CK054_XENLA   Q6GME2      Ester hydrolase C11orf54 homolog                                    E:0            
  comp234419_c0_seq2    bd_rv        -7.77   1.16     3.74E-23   7.35E-19   0.01    0        0       0       1.75     1.95    1.16    1.45    2.04    FA73B_XENLA   Q6GR21      Protein FAM73B                                                      E:0            
  comp239933_c4_seq3    rv           9.74    0.31     1.57E-13   1.03E-09   4.41    2.28     2.54    0       0        0       0.4     3.79    0.9     AP4S1_BOVIN   Q3ZBB6      AP-4 complex subunit sigma-1                                        E:5e-86        
  comp235822_c0_seq8    rv           4.32    2.04     7.02E-16   6.89E-12   0       1.01     0       0.23    0.06     0.16    2.78    3.2     2.94    NB5R3_BOVIN   P07514      NADH-cytochrome b5 reductase 3                                      E:2e-161       
  comp236322_c0_seq1    rv           2.28    3.56     2.71E-08   1.33E-04   1.63    1.33     2.11    1.16    0.88     1.09    4.48    3.56    6.94    POL2_MOUSE    P11369      Retrovirus-related Pol polyprotein LINE-1                           E:3e-172       
  comp215007_c0_seq2    rv           -1.89   -0.28    3.24E-05   3.09E-02   2.06    1.91     0.9     1.06    1.57     1.96    0.34    0.59    0.31    ABCA8_HUMAN   O94911      ATP-binding cassette sub-family A member 8                          E:1e-87        
  comp240300_c2_seq5    rv           -1.97   2.66     3.58E-06   6.39E-03   5.84    3.81     2.69    3.15    8.03     7.01    1.41    1.61    1.52    CI064_HUMAN   Q5T6V5      UPF0553 protein C9orf64                                             E:6e-167       
  comp227497_c0_seq1    rv           -2.01   7.16     2.68E-06   5.25E-03   8.5     27.9     43.39   69.64   112.17   154.2   17.51   27.83   35.5    CP7A1_HUMAN   P22680      Cholesterol 7-alpha-monooxygenase                                   E:0            

. bd = *Bd* vs. control, rv = *Ranavirus* vs. control, bd_rv = *Bd* vs. *Ranavirus*

Five transcripts were significantly differentially expressed in both the *Ranavirus* vs. control and *Bd* vs. control sets (FDR\<0.05). Three of these were up-regulated after exposure to both pathogens (including the two with the highest logFC change values of all transcripts in both treatments) and two were down-regulated. The AP-4 complex subunit sigma-1 is the only one of these five transcripts that was successfully annotated, and was associated with the highest logFC increase in both treatments (10.9 and 9.74 fold up-regulation in *Bd*, and *Ranavirus* treatments respectively). At the FDR threshold of p\<0.10, ten transcripts were significantly differentially expressed in both the *Bd* vs. control and *Ranavirus* vs. control comparisons. Of these, four were up-regulated in both comparisons and six down-regulated. Four annotations in addition to the AP-4 complex were obtained, including (i) Cholesterol 7-alpha-monooxygenase which may be involved in xenobiotic metabolism, (ii) Acyl-coenzyme A synthetase ACSM3, a mitochondrial gene involved in lipid and/or fatty acid metabolism, (iii) Protein CutA homolog possibly involved in metal ion response, and (iv) Protein FAM136A, another mitochondrial protein. Differentially expressed transcripts with annotation are summarized in [Table 3](#pone.0130500.t003){ref-type="table"}, and the full data is available in [S1 File](#pone.0130500.s005){ref-type="supplementary-material"}.

GO term enrichment {#sec010}
------------------

Enriched GO terms ([Table 4](#pone.0130500.t004){ref-type="table"}; adjusted P-value\<0.05) clustered in cell signalling, immunity, inflammation and metabolism. In total, 103 GO terms were significantly enriched in animals challenged with *Bd* (at 5% level after adjusting for multiple comparisons) compared to the reference set (see [Table 4](#pone.0130500.t004){ref-type="table"}). When parent GO terms were examined, 14 of the 20 differentially expressed transcripts under the "metabolic process" parent GO term (GO:0008152) were up-regulated in *Bd* compared to controls. All transcripts related to "Biological regulation" (GO:0065007) were up-regulated. Immune system processes (GO:0006958), inflammatory responses (GO:0006954) and response to stimulus (GO:0050896) were also generally up-regulated (driven by complement activation) though there was also a down-regulation of Immunoglobulin J chain. No GO terms were enriched in the *Ranavirus* challenged animals, and no GO terms (regardless of treatment) were significantly enriched when differentially expressed transcripts in the FDR \< 0.05 lists only were used for GO enrichment analyses.

10.1371/journal.pone.0130500.t004

###### Enriched GO terms associated with differentially expressed transcripts in the *Bd* vs. control comparison (adjusted P-value \<0.05).

![](pone.0130500.t004){#pone.0130500.t004g}

  GO term description                                                                                                         adjusted PValue   pValue     GO ID        Total Annotated seqs   Individual GO term total   Total DE set   Individual GO term total in DE set
  --------------------------------------------------------------------------------------------------------------------------- ----------------- ---------- ------------ ---------------------- -------------------------- -------------- ------------------------------------
  cellular ketone metabolic process                                                                                           5.51E-08          1.64E-10   GO:0042180   36661                  1876                       92             23
  organic acid metabolic process                                                                                              5.51E-08          1.73E-10   GO:0006082   36661                  1881                       92             23
  oxoacid metabolic process                                                                                                   5.51E-08          1.05E-10   GO:0043436   36661                  1834                       92             23
  carboxylic acid metabolic process                                                                                           5.51E-08          1.05E-10   GO:0019752   36661                  1834                       92             23
  negative regulation of endopeptidase activity                                                                               1.04E-05          4.08E-08   GO:0010951   36661                  130                        92             7
  monocarboxylic acid metabolic process                                                                                       1.11E-05          5.23E-08   GO:0032787   36661                  1047                       92             15
  small molecule metabolic process                                                                                            5.84E-05          3.21E-07   GO:0044281   36661                  5068                       92             32
  negative regulation of peptidase activity                                                                                   1.14E-04          7.16E-07   GO:0010466   36661                  198                        92             7
  regulation of lipid biosynthetic process                                                                                    1.46E-04          1.03E-06   GO:0046890   36661                  209                        92             7
  succinate metabolic process                                                                                                 1.62E-04          1.27E-06   GO:0006105   36661                  9                          92             3
  complement activation, classical pathway                                                                                    3.95E-04          3.41E-06   GO:0006958   36661                  161                        92             6
  humoral immune response mediated by circulating immunoglobulin                                                              4.03E-04          3.79E-06   GO:0002455   36661                  164                        92             6
  humoral immune response                                                                                                     4.07E-04          4.15E-06   GO:0006959   36661                  258                        92             7
  positive regulation of G-protein coupled receptor protein signaling pathway                                                 5.09E-04          5.59E-06   GO:0045745   36661                  46                         92             4
  positive regulation of lipid storage                                                                                        8.41E-04          9.90E-06   GO:0010884   36661                  53                         92             4
  regulation of triglyceride biosynthetic process                                                                             9.83E-04          1.23E-05   GO:0010866   36661                  56                         92             4
  complement activation, alternative pathway                                                                                  1.19E-03          1.59E-05   GO:0006957   36661                  124                        92             5
  activation of plasma proteins involved in acute inflammatory response                                                       1.39E-03          2.08E-05   GO:0002541   36661                  221                        92             6
  complement activation                                                                                                       1.39E-03          1.97E-05   GO:0006956   36661                  219                        92             6
  immunoglobulin mediated immune response                                                                                     2.25E-03          3.53E-05   GO:0016064   36661                  243                        92             6
  B cell mediated immunity                                                                                                    2.29E-03          3.78E-05   GO:0019724   36661                  246                        92             6
  negative regulation of hydrolase activity                                                                                   2.42E-03          4.32E-05   GO:0051346   36661                  508                        92             8
  regulation of triglyceride metabolic process                                                                                2.42E-03          4.37E-05   GO:0090207   36661                  77                         92             4
  fatty acid metabolic process                                                                                                2.59E-03          5.09E-05   GO:0006631   36661                  674                        92             9
  regulation of endopeptidase activity                                                                                        2.59E-03          5.09E-05   GO:0052548   36661                  381                        92             7
  regulation of peptidase activity                                                                                            2.71E-03          5.52E-05   GO:0052547   36661                  386                        92             7
  lipid metabolic process                                                                                                     3.48E-03          7.65E-05   GO:0006629   36661                  2370                       92             17
  lymphocyte mediated immunity                                                                                                3.48E-03          7.59E-05   GO:0002449   36661                  279                        92             6
  regulation of lipid storage                                                                                                 3.53E-03          8.04E-05   GO:0010883   36661                  90                         92             4
  regulation of activation of membrane attack complex                                                                         3.70E-03          9.28E-05   GO:0001969   36661                  6                          92             2
  positive regulation of complement activation                                                                                3.70E-03          9.28E-05   GO:0045917   36661                  6                          92             2
  positive regulation of activation of membrane attack complex                                                                3.70E-03          9.28E-05   GO:0001970   36661                  6                          92             2
  regulation of lipid metabolic process                                                                                       3.83E-03          9.91E-05   GO:0019216   36661                  424                        92             7
  positive regulation of glucose transport                                                                                    4.54E-03          1.21E-04   GO:0010828   36661                  100                        92             4
  protein maturation by peptide bond cleavage                                                                                 4.85E-03          1.45E-04   GO:0051605   36661                  314                        92             6
  adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   4.85E-03          1.37E-04   GO:0002460   36661                  311                        92             6
  protein maturation                                                                                                          4.85E-03          1.35E-04   GO:0051604   36661                  446                        92             7
  cellular respiration                                                                                                        4.85E-03          1.43E-04   GO:0045333   36661                  197                        92             5
  regulation of glucose transport                                                                                             5.26E-03          1.61E-04   GO:0010827   36661                  202                        92             5
  sterol metabolic process                                                                                                    5.74E-03          1.80E-04   GO:0016125   36661                  327                        92             6
  leukocyte mediated immunity                                                                                                 7.24E-03          2.33E-04   GO:0002443   36661                  343                        92             6
  adaptive immune response                                                                                                    8.24E-03          2.72E-04   GO:0002250   36661                  353                        92             6
  acute inflammatory response                                                                                                 8.60E-03          3.11E-04   GO:0002526   36661                  362                        92             6
  positive regulation of type II hypersensitivity                                                                             8.60E-03          3.38E-04   GO:0002894   36661                  11                         92             2
  positive regulation of type IIa hypersensitivity                                                                            8.60E-03          3.38E-04   GO:0001798   36661                  11                         92             2
  positive regulation of myeloid leukocyte mediated immunity                                                                  8.60E-03          3.38E-04   GO:0002888   36661                  11                         92             2
  regulation of type II hypersensitivity                                                                                      8.60E-03          3.38E-04   GO:0002892   36661                  11                         92             2
  regulation of type IIa hypersensitivity                                                                                     8.60E-03          3.38E-04   GO:0001796   36661                  11                         92             2
  activation of immune response                                                                                               8.60E-03          3.32E-04   GO:0002253   36661                  517                        92             7
  respiratory electron transport chain                                                                                        8.60E-03          3.09E-04   GO:0022904   36661                  52                         92             3
  steroid metabolic process                                                                                                   1.01E-02          4.03E-04   GO:0008202   36661                  534                        92             7
  translation                                                                                                                 1.04E-02          4.26E-04   GO:0006412   36661                  539                        92             7
  generation of precursor metabolites and energy                                                                              1.06E-02          4.40E-04   GO:0006091   36661                  714                        92             8
  regulation of G-protein coupled receptor protein signaling pathway                                                          1.06E-02          4.51E-04   GO:0008277   36661                  141                        92             4
  regulation of acute inflammatory response to antigenic stimulus                                                             1.20E-02          5.56E-04   GO:0002864   36661                  14                         92             2
  positive regulation of acute inflammatory response to antigenic stimulus                                                    1.20E-02          5.56E-04   GO:0002866   36661                  14                         92             2
  positive regulation of hypersensitivity                                                                                     1.20E-02          5.56E-04   GO:0002885   36661                  14                         92             2
  regulation of hypersensitivity                                                                                              1.20E-02          5.56E-04   GO:0002883   36661                  14                         92             2
  positive regulation of protein amino acid phosphorylation                                                                   1.20E-02          5.19E-04   GO:0001934   36661                  399                        92             6
  organic acid biosynthetic process                                                                                           1.21E-02          5.81E-04   GO:0016053   36661                  568                        92             7
  carboxylic acid biosynthetic process                                                                                        1.21E-02          5.81E-04   GO:0046394   36661                  568                        92             7
  protein processing                                                                                                          1.45E-02          7.04E-04   GO:0016485   36661                  423                        92             6
  positive regulation of inflammatory response to antigenic stimulus                                                          1.45E-02          7.31E-04   GO:0002863   36661                  16                         92             2
  energy derivation by oxidation of organic compounds                                                                         1.45E-02          7.30E-04   GO:0015980   36661                  426                        92             6
  positive regulation of phosphorylation                                                                                      1.54E-02          7.85E-04   GO:0042327   36661                  432                        92             6
  regulation of inflammatory response to antigenic stimulus                                                                   1.79E-02          9.28E-04   GO:0002861   36661                  18                         92             2
  regulation of transport                                                                                                     2.08E-02          1.14E-03   GO:0051049   36661                  1705                       92             12
  cellular lipid metabolic process                                                                                            2.08E-02          1.12E-03   GO:0044255   36661                  1701                       92             12
  positive regulation of phosphorus metabolic process                                                                         2.08E-02          1.16E-03   GO:0010562   36661                  466                        92             6
  positive regulation of phosphate metabolic process                                                                          2.08E-02          1.16E-03   GO:0045937   36661                  466                        92             6
  cholesterol metabolic process                                                                                               2.08E-02          1.11E-03   GO:0008203   36661                  309                        92             5
  positive regulation of protein maturation by peptide bond cleavage                                                          2.24E-02          1.27E-03   GO:0010954   36661                  21                         92             2
  positive regulation of immune response                                                                                      2.26E-02          1.29E-03   GO:0050778   36661                  652                        92             7
  tricarboxylic acid cycle                                                                                                    2.48E-02          1.44E-03   GO:0006099   36661                  88                         92             3
  electron transport chain                                                                                                    2.51E-02          1.48E-03   GO:0022900   36661                  194                        92             4
  regulation of cellular ketone metabolic process                                                                             2.57E-02          1.53E-03   GO:0010565   36661                  196                        92             4
  cellular amino acid biosynthetic process                                                                                    2.63E-02          1.59E-03   GO:0008652   36661                  198                        92             4
  acetyl-CoA catabolic process                                                                                                2.67E-02          1.63E-03   GO:0046356   36661                  92                         92             3
  small molecule catabolic process                                                                                            2.74E-02          1.70E-03   GO:0044282   36661                  1314                       92             10
  negative regulation of catalytic activity                                                                                   2.80E-02          1.76E-03   GO:0043086   36661                  886                        92             8
  positive regulation of extracellular matrix constituent secretion                                                           3.60E-02          2.51E-03   GO:0003331   36661                  1                          92             1
  regulation of extracellular matrix constituent secretion                                                                    3.60E-02          2.51E-03   GO:0003330   36661                  1                          92             1
  physiological cardiac muscle hypertrophy                                                                                    3.60E-02          2.51E-03   GO:0003301   36661                  1                          92             1
  cell growth involved in cardiac muscle cell development                                                                     3.60E-02          2.51E-03   GO:0061049   36661                  1                          92             1
  dicarboxylic acid metabolic process                                                                                         3.60E-02          2.51E-03   GO:0043648   36661                  107                        92             3
  fibroblast proliferation                                                                                                    3.60E-02          2.51E-03   GO:0048144   36661                  1                          92             1
  coenzyme catabolic process                                                                                                  3.60E-02          2.38E-03   GO:0009109   36661                  105                        92             3
  response to muscle activity involved in regulation of muscle adaptation                                                     3.60E-02          2.51E-03   GO:0014873   36661                  1                          92             1
  aerobic respiration                                                                                                         3.60E-02          2.38E-03   GO:0009060   36661                  105                        92             3
  cellular amino acid metabolic process                                                                                       3.71E-02          2.62E-03   GO:0006520   36661                  739                        92             7
  regulation of immune response                                                                                               3.76E-02          2.69E-03   GO:0050776   36661                  949                        92             8
  positive regulation of B cell mediated immunity                                                                             3.95E-02          2.94E-03   GO:0002714   36661                  32                         92             2
  positive regulation of immunoglobulin mediated immune response                                                              3.95E-02          2.94E-03   GO:0002891   36661                  32                         92             2
  positive regulation vascular endothelial growth factor production                                                           3.95E-02          2.94E-03   GO:0010575   36661                  32                         92             2
  regulation of vascular endothelial growth factor production                                                                 3.95E-02          2.94E-03   GO:0010574   36661                  32                         92             2
  purine ribonucleoside triphosphate metabolic process                                                                        4.11E-02          3.09E-03   GO:0009205   36661                  567                        92             6
  positive regulation of acute inflammatory response                                                                          4.30E-02          3.32E-03   GO:0002675   36661                  34                         92             2
  purine nucleoside triphosphate metabolic process                                                                            4.30E-02          3.34E-03   GO:0009144   36661                  576                        92             6
  oxidation reduction                                                                                                         4.30E-02          3.33E-03   GO:0055114   36661                  243                        92             4
  ribonucleoside triphosphate metabolic process                                                                               4.63E-02          3.64E-03   GO:0009199   36661                  586                        92             6
  positive regulation of humoral immune response                                                                              4.68E-02          3.71E-03   GO:0002922   36661                  36                         92             2
  cofactor catabolic process                                                                                                  4.76E-02          3.81E-03   GO:0051187   36661                  124                        92             3
  heterocycle metabolic process                                                                                               4.96E-02          4.01E-03   GO:0046483   36661                  1242                       92             9

Discussion {#sec011}
==========

We investigated the response of an anuran host (*R*. *temporaria*) to the fungal pathogen *Bd* and the viral pathogen, *Ranavirus*, and detected a significant transcriptional response to *Bd*. Enriched GO terms involved the major arms of the immune response (innate and adaptive immunity and complement activation) as well as metabolic processes. Elements of the adaptive immune response were significantly differentially expressed in animals exposed to *Bd* and those exposed to *Ranavirus*, and this transcriptional response occurred at only four days post-exposure and before signs of disease consistent with ranavirosis were observed. Despite this, the overall response to *Ranavirus* was extremely limited. Variation between pools within treatments resulted in low power to detect differential expression when accounting for multiple comparisons (False Discovery Rate). However, this conservative approach allows confidence in the results and likely includes the genes with the largest transcriptional changes.

Perhaps the most notable result is the strong up-regulation of elements of the adaptive immunity, in response to either pathogen. The highest log fold-change for both pathogen treatments was successfully annotated to the AP-4 complex subunit sigma-1 gene (AP4S1). This is a subunit of a protein coat that is involved in targeting proteins from the trans-Golgi network to the endosomal-lysosomal system (<http://www.uniprot.org/uniprot/Q9Y587>). The trans-Golgi network is the location for the loading of cytokines (cytokines modulate the balance between the humoral and cell-based adaptive immune responses) with signal peptides into vesicles or carriers for delivery to the cell surface or other organelles \[[@pone.0130500.ref043]\]. The endosomal-lysosomal proteolysis system appears to be crucial in the immune system, in particular by binding class II MHC molecules to create ligands for antigen recognition by the T lymphocyte system. This process of antigen processing is important for immunity to pathogens as well as for the identification of self-peptides \[[@pone.0130500.ref044]\]. This result indicates that AP4S1 may be a particularly important candidate gene for future studies of amphibian host-pathogen biology. To date, we are unaware of any studies focusing on this gene in this context.

It is also notable that Interferon-stimulated 20 kDa exonuclease-like 2 and multiple versions of an Interferon-induced very large GTPase 1 were significantly up-regulated in the *Bd* treatment ([Table 2](#pone.0130500.t002){ref-type="table"}). Interferon-induced very large GTPases are thought to mobilise effectors against a broad range of invading pathogens \[[@pone.0130500.ref045]\]. This result suggests that we have sampled these frogs after an initial innate response and at the point of mobilising other pathways. The result further suggests that these hosts are mounting a major phagocytic response to *Bd* challenge, an anti-fungal response which has previously been shown to be unimpaired during experimental chytrid infection \[[@pone.0130500.ref046]\].

We found a much stronger transcriptional response to *Bd* exposure than to *Ranavirus*. Our results broadly reflect what is seen in the wild. *R*. *temporaria* populations in the UK have undergone serious declines in the face of recurrent FV3-like *Ranavirus* die-offs \[[@pone.0130500.ref005]\] and are involved in multi-host mass mortality events associated with infection with a newly emerging *Ranavirus* lineage in Spain \[[@pone.0130500.ref007]\]. This host is highly susceptible to *Ranavirus* and it seems likely that infected individuals are failing to mount an effective immune response. In contrast, common frogs are considered relatively resistant to *Bd* \[[@pone.0130500.ref009]\], which may reflect effective immunity. Our observations of a weak transcriptional response to *Ranavirus* are therefore consistent with the higher pathogenicity of *Ranavirus* relative to *Bd* in this host as well as potential immune evasion of *Ranavirus* (reviewed in \[[@pone.0130500.ref017]\]).

However, the limited overall response to *Ranavirus* challenge that we detected was surprising in the light of previous work. Cotter *et al*. exposed Ambystomatid salamanders to ATV and used a custom microarray to measure host response in spleens at time-points between 24 hours and 6 days \[[@pone.0130500.ref015]\]. Ambystomatids are naturally infected with ATV in North America and are highly susceptible \[[@pone.0130500.ref047]\] but immune response (including phagocytosis, cytokine signalling, and complement activation) was detected as early as 24 hours post exposure and transcriptional response increased through the six day experimental period \[[@pone.0130500.ref015]\]. Differences in methodological approach and host-pathogen system might explain the contrasting findings. Tissue type, dose and exposure route all varied between studies and the host species investigated are highly divergent. The viruses utilised are also divergent. ATV is closely related to fish *Ranaviruses* and may represent a recent host jump \[[@pone.0130500.ref048]\]. ATV also seems more specialized for salamanders over other amphibians \[[@pone.0130500.ref049]\]. On the other hand, FV3-like viruses have been more frequently implicated in multi-host die-offs \[[@pone.0130500.ref002]\] (and may therefore represent better immune evaders) and are the more derived lineage of amphibian-like ranaviruses.

Previous work has shown increased expression of Immunoglobulin Y and activation-induced cytidine deaminase (AID) after *Ranavirus* (FV3) exposure in *Xenopus laevis*, indicating that B-cells are activated, and antibodies to *Ranavirus* have been detected two to six months post-exposure in this host species \[[@pone.0130500.ref050]--[@pone.0130500.ref052]\]. As well as this adaptive immune response, there was a rapid up-regulation of pro-inflammatory genes (Arginase 1, IL-1B, TNF-a, largely produced by macrophages), and an increased abundance of macrophages and antimicrobial peptides, which are known to inactivate FV3 *in vitro* \[[@pone.0130500.ref052]--[@pone.0130500.ref054]\]. Other studies indicate that we might expect to detect changes in MHC class I gene expression under *Ranavirus* infection, however it is clear that MHC expression is age-dependent. Pre-metamorphic *Xenopus* tadpoles do not express MHC class Ia genes, while adults do--in juveniles, the stage used in our experiment, expression is weaker than in adults \[[@pone.0130500.ref055]\]. We saw evidence for an adaptive immune response being initiated (AP4S1 up-regulation) but little evidence of further responses in our *Ranavirus* vs. control comparison.

Rosenblum *et al*. also reported significant transcriptional changes in Interferon-related genes in *Bd*-exposed animals, although they found many of these were only expressed at 16 days as opposed to 3 days post-exposure \[[@pone.0130500.ref012]\]. Our data demonstrates that in *R*. *temporaria*, these pathways are already active four days post-exposure. *Bd* may suppress T-cell mediated responses to infection \[[@pone.0130500.ref013]\] and resistance to *Bd* may be partly due to an ability to overcome this \[[@pone.0130500.ref011]\]. Here we have demonstrated the enrichment of lymphocyte and leukocyte mediated immunity in *R*. *temporaria*. In addition to immunological responses, Rosenblum *et al*. reported differential expression in a range of skin integrity, cellular stress, and homeostasis genes---the majority of these detected 16 days post-exposure \[[@pone.0130500.ref012]\]. *Bd* disruption of host skin integrity is a key disease process \[[@pone.0130500.ref010]\] and resistant hosts may mitigate this effect through increased expression of genes contributing to skin structure \[[@pone.0130500.ref011]\]. Although we sampled livers and not skin, we also observed this type of structural response to *Bd* through up-regulation of genes involved in fibroblast proliferation as well as up-regulation of actin and Galectin-3.

Previous work has shown that particular MHC class IIB alleles are associated with host resistance to *Bd* across a range of hosts varying in their susceptibility to the pathogen \[[@pone.0130500.ref056]\]. Rosenblum *et al*. reported down-regulation of MHC class I and II in the spleen and up-regulation of MHC class I and II in the skin in *R*. *mucosa* experimentally infected with *Bd*, however these were predominantly shown after 16 days post-exposure and not after only three days post-exposure \[[@pone.0130500.ref012]\]. We saw no changes in MHC expression in animals exposed to *Bd*.

A more relaxed false discovery rate threshold is expected to yield an increased number of differentially expressed genes but this effect appeared stronger in our *Bd* treatment. The relatively large number of genes withstanding the less stringent FDR correction (0.1) relative to the more conservative one (0.05) suggests that a large number of genes were differentially expressed between treatments but that the amplitude of this change was only modest. Our experimental design involved sampling animals at an early time-point, four days after exposure and prior to any observed mortality or observed signs of disease. This design has enabled identification of changes due to pathogen exposure rather than merely identifying differences between healthy and dying hosts. Previous experiments have pointed to reduced transcriptional responses at early time points post-exposure (3 days) relative to late time-points (16 days) in *Rana* species exposed to *Bd*, with the majority of transcriptional changes only becoming significant later \[[@pone.0130500.ref012]\]. Innate immune response to *Ranavirus* in *X*. *laevis* peaks at six days post-exposure, with adaptive immunity still detectable at 2--6 months post-exposure \[[@pone.0130500.ref057]\]. In contrast, we have demonstrated that certain adaptive host transcriptional responses do occur early for both pathogens examined.

This study demonstrates the utility of using RNAseq with non-model organisms to identify loci that may be important in host responses to pathogens. Amphibians are a highly threatened group, faced with catastrophic declines driven in part by emerging infectious diseases. Whole genome data is currently only available for a single amphibian genus (*Xenopus*). As such, our transcriptome data for *R*. *temporaria* provides a valuable resource for another genus \[[@pone.0130500.ref058]\], much-needed insight into amphibian immunity, as well as information on specific responses to the two most important multi-host pathogens affecting amphibians. We were also able to identify candidate genes that could serve as markers for understanding the impacts of disease in wild populations and the adaptive potential of populations that are under threat. While this study has provided crucial insights into amphibian gene expression following exposure to pathogens, comparisons across life-history stages, time points post-exposure, and source populations with different previous infection statuses and genetic diversity will all be necessary to gain a more complete picture of the transcriptional responses to amphibian disease. We foresee this line of research offering exciting possibilities for the selection of individuals with disease resistance for captive breeding programmes for conservation.
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